Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET.

Related Articles

Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET.

Alzheimers Dement. 2018 Apr 18;:

Authors: Altomare D, Ferrari C, Festari C, Guerra UP, Muscio C, Padovani A, Frisoni GB, Boccardi M, Incremental Diagnostic Value of Amyloid PET With [(18)F]-Florbetapir (INDIA-FBP) Working Group

Abstract
INTRODUCTION: We test the hypothesis that amyloid-PET prescriptions, considered appropriate based on the Amyloid Imaging Taskforce (AIT) criteria, lead to greater clinical utility than AIT-inappropriate prescriptions.
METHODS: We compared the clinical utility between patients who underwent amyloid-PET appropriately or inappropriately and among the subgroups of patients defined by the AIT criteria. Finally, we performed logistic regressions to identify variables associated with clinical utility.
RESULTS: We identified 171 AIT-appropriate and 67 AIT-inappropriate patients. AIT-appropriate and AIT-inappropriate cases did not differ in any outcomes of clinical utility (P > .05). Subgroup analysis denoted both expected and unexpected results. The logistic regressions outlined the primary role of clinical picture and clinical or neuropsychological profile in identifying patients benefitting from amyloid-PET.
DISCUSSION: Contrary to our hypothesis, also AIT-inappropriate prescriptions were associated with clinical utility. Clinical or neuropsychological variables, not taken into account by the AIT criteria, may help further refine criteria for appropriateness.

PMID: 29679576 [PubMed - as supplied by publisher]

https://ift.tt/2HRmJdd